Titre : Peptides natriurétiques

Peptides natriurétiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Peptides natriurétiques : Questions médicales les plus fréquentes", "headline": "Peptides natriurétiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Peptides natriurétiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-19", "dateModified": "2025-05-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Peptides natriurétiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hormones peptidiques", "url": "https://questionsmedicales.fr/mesh/D036361", "about": { "@type": "MedicalCondition", "name": "Hormones peptidiques", "code": { "@type": "MedicalCode", "code": "D036361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Facteur atrial natriurétique", "alternateName": "Atrial Natriuretic Factor", "url": "https://questionsmedicales.fr/mesh/D009320", "about": { "@type": "MedicalCondition", "name": "Facteur atrial natriurétique", "code": { "@type": "MedicalCode", "code": "D009320", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548.585.500" } } }, { "@type": "MedicalWebPage", "name": "Peptide natriurétique de type C", "alternateName": "Natriuretic Peptide, C-Type", "url": "https://questionsmedicales.fr/mesh/D020098", "about": { "@type": "MedicalCondition", "name": "Peptide natriurétique de type C", "code": { "@type": "MedicalCode", "code": "D020098", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.644.548.585.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Peptides natriurétiques", "alternateName": "Natriuretic Peptides", "code": { "@type": "MedicalCode", "code": "D045265", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jens P Goetze", "url": "https://questionsmedicales.fr/author/Jens%20P%20Goetze", "affiliation": { "@type": "Organization", "name": "Department of Clinical Biochemistry, Rigshospitalet University Hospital, Copenhagen, Denmark." } }, { "@type": "Person", "name": "Speranza Rubattu", "url": "https://questionsmedicales.fr/author/Speranza%20Rubattu", "affiliation": { "@type": "Organization", "name": "Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. speranzadonatella.rubattu@uniroma1.it." } }, { "@type": "Person", "name": "John C Burnett", "url": "https://questionsmedicales.fr/author/John%20C%20Burnett", "affiliation": { "@type": "Organization", "name": "Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA. Electronic address: burnett.john@mayo.edu." } }, { "@type": "Person", "name": "Naoto Minamino", "url": "https://questionsmedicales.fr/author/Naoto%20Minamino", "affiliation": { "@type": "Organization", "name": "Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Suita, Japan." } }, { "@type": "Person", "name": "Katherine N Bachmann", "url": "https://questionsmedicales.fr/author/Katherine%20N%20Bachmann", "affiliation": { "@type": "Organization", "name": "Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G)." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population.", "datePublished": "2022-10-15", "url": "https://questionsmedicales.fr/article/36292752", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13101867" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.", "datePublished": "2023-11-14", "url": "https://questionsmedicales.fr/article/37977159", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2213-2600(23)00376-4" } }, { "@type": "ScholarlyArticle", "name": "Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.", "datePublished": "2023-03-09", "url": "https://questionsmedicales.fr/article/36890354", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00415-023-11617-1" } }, { "@type": "ScholarlyArticle", "name": "Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.", "datePublished": "2023-02-03", "url": "https://questionsmedicales.fr/article/36769297", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms24032975" } }, { "@type": "ScholarlyArticle", "name": "Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment.", "datePublished": "2022-06-06", "url": "https://questionsmedicales.fr/article/35699625", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.20452/pamw.16271" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Peptides", "item": "https://questionsmedicales.fr/mesh/D010455" }, { "@type": "ListItem", "position": 4, "name": "Hormones peptidiques", "item": "https://questionsmedicales.fr/mesh/D036361" }, { "@type": "ListItem", "position": 5, "name": "Peptides natriurétiques", "item": "https://questionsmedicales.fr/mesh/D045265" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Peptides natriurétiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Peptides natriurétiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Peptides natriurétiques", "description": "Comment diagnostiquer une insuffisance cardiaque ?\nQuels tests mesurent les peptides natriurétiques ?\nQuels symptômes indiquent un test de peptides natriurétiques ?\nQuelle est la valeur normale des peptides natriurétiques ?\nComment interpréter un taux élevé de BNP ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Peptides natriurétiques", "description": "Quels sont les symptômes des peptides natriurétiques élevés ?\nLes peptides natriurétiques causent-ils des symptômes ?\nComment les symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils différents chez les hommes et les femmes ?\nQuels signes cliniques sont associés aux peptides natriurétiques ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Peptides natriurétiques", "description": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?\nL'alimentation influence-t-elle les niveaux de peptides natriurétiques ?\nL'exercice régulier aide-t-il à prévenir des niveaux élevés ?\nLe stress affecte-t-il les peptides natriurétiques ?\nLes contrôles médicaux réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Peptides natriurétiques", "description": "Quels traitements sont basés sur les peptides natriurétiques ?\nLes peptides natriurétiques sont-ils utilisés en thérapie ?\nComment les diurétiques agissent-ils sur les peptides natriurétiques ?\nLes traitements affectent-ils les niveaux de BNP ?\nQuels sont les effets secondaires des traitements ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Peptides natriurétiques", "description": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?\nLes peptides natriurétiques sont-ils liés à des maladies rénales ?\nComment les complications cardiovasculaires se manifestent-elles ?\nLes complications sont-elles réversibles ?\nQuels facteurs aggravent les complications liées aux peptides natriurétiques ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Peptides natriurétiques", "description": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?\nLe tabagisme influence-t-il les niveaux de peptides natriurétiques ?\nL'âge est-il un facteur de risque ?\nLe stress chronique influence-t-il la santé cardiaque ?\nL'inactivité physique est-elle un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une insuffisance cardiaque ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic repose sur des examens cliniques, échographies et dosages de peptides natriurétiques." } }, { "@type": "Question", "name": "Quels tests mesurent les peptides natriurétiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sanguins mesurent le BNP ou le NT-proBNP pour évaluer la fonction cardiaque." } }, { "@type": "Question", "name": "Quels symptômes indiquent un test de peptides natriurétiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdème et palpitations peuvent justifier un test de peptides natriurétiques." } }, { "@type": "Question", "name": "Quelle est la valeur normale des peptides natriurétiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les valeurs normales varient, mais un BNP < 100 pg/ml est souvent considéré comme normal." } }, { "@type": "Question", "name": "Comment interpréter un taux élevé de BNP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un taux élevé de BNP indique souvent une insuffisance cardiaque ou une surcharge volumique." } }, { "@type": "Question", "name": "Quels sont les symptômes des peptides natriurétiques élevés ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdème et douleurs thoraciques peuvent être présents." } }, { "@type": "Question", "name": "Les peptides natriurétiques causent-ils des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont des biomarqueurs. Les symptômes proviennent de l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent être plus subtils chez les personnes âgées, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Les symptômes sont-ils différents chez les hommes et les femmes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes peuvent présenter des symptômes atypiques, rendant le diagnostic plus complexe." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés aux peptides natriurétiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent l'œdème périphérique, la tachycardie et l'hypertension." } }, { "@type": "Question", "name": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain, contrôler la pression artérielle et éviter le tabac." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les niveaux de peptides natriurétiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en sodium peut augmenter la pression artérielle et les peptides natriurétiques." } }, { "@type": "Question", "name": "L'exercice régulier aide-t-il à prévenir des niveaux élevés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier améliore la santé cardiaque et peut réduire les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Le stress affecte-t-il les peptides natriurétiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut aggraver les problèmes cardiaques et augmenter les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes cardiaques." } }, { "@type": "Question", "name": "Quels traitements sont basés sur les peptides natriurétiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent les diurétiques, les inhibiteurs de l'ACE et les bêtabloquants." } }, { "@type": "Question", "name": "Les peptides natriurétiques sont-ils utilisés en thérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des analogues de peptides natriurétiques sont utilisés pour traiter l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment les diurétiques agissent-ils sur les peptides natriurétiques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les diurétiques réduisent le volume sanguin, ce qui peut diminuer les niveaux de peptides natriurétiques." } }, { "@type": "Question", "name": "Les traitements affectent-ils les niveaux de BNP ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement efficace peut réduire les niveaux de BNP, indiquant une amélioration." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure hypotension, déséquilibres électrolytiques et fatigue." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent l'insuffisance cardiaque, l'arythmie et l'hypertension." } }, { "@type": "Question", "name": "Les peptides natriurétiques sont-ils liés à des maladies rénales ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés peuvent indiquer une insuffisance rénale associée à des problèmes cardiaques." } }, { "@type": "Question", "name": "Comment les complications cardiovasculaires se manifestent-elles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des douleurs thoraciques, des essoufflements et des syncopes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie." } }, { "@type": "Question", "name": "Quels facteurs aggravent les complications liées aux peptides natriurétiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension, le diabète et l'obésité aggravent les complications cardiaques et rénales." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'hypertension, le diabète, l'obésité et les antécédents familiaux." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les niveaux de peptides natriurétiques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque de maladies cardiaques et peut affecter les niveaux de peptides." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'insuffisance cardiaque augmente avec l'âge en raison de divers facteurs physiologiques." } }, { "@type": "Question", "name": "Le stress chronique influence-t-il la santé cardiaque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques." } }, { "@type": "Question", "name": "L'inactivité physique est-elle un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le manque d'exercice augmente le risque de maladies cardiovasculaires et d'insuffisance cardiaque." } } ] } ] }

Sources (1719 au total)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.

From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of ba... TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressant... Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54... Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and stand... UK Medical Research Council, UK National Institute for Health Research Cambridge Biomedical Research Centre, Eli Lilly and Company, Alexion Pharmaceuticals, and Addenbrooke's Charitable Trust....

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.

The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled period (RCP) ... Data were analyzed from 86 patients who received ravulizumab in the CHAMPION MG RCP. Ravulizumab dosing was weight-based: initial loading dose of 2400/2700/3000 mg on Day 1 and maintenance doses of 30... Target serum ravulizumab concentrations (> 175 µg/mL) were achieved immediately after the first ravulizumab dose (within 30 min of infusion completion) and maintained throughout the 26-week treatment ... PK/PD evidence supports the use of ravulizumab every 8 weeks for immediate, complete, and sustained inhibition of terminal complement C5 in adults with AChR Ab+ gMG.... ClinicalTrials.gov ID: NCT03920293 (April 18, 2019)....

Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.

Immune checkpoint inhibitors (ICIs) have made an important contribution to the survival of patients with certain cancers. ICIs interrupt co-inhibitory signaling pathways mediated by programmed cell de...

C5 palsy following esophageal diverticulum resection.

C5 palsy (C5P) is a recognized potential postoperative complication of cervical spine surgery but has rarely been reported following an open esophageal diverticulectomy.... A 61-year-old underwent an open esophageal diverticulectomy for symptomatic Zencker's diverticulum.... Postoperatively, she presented with right upper extremity weakness and sensory deficits consistent with a C5P that was later confirmed by electromyography.... The potential for C5P after esophageal diverticulectomy for symptomatic Zencker's diverticulum is rare. Postoperative recognition and appropriate management are critical to recovery....

Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are two rare and severe conditions caused by chronic complement (C') system dysregulation. Treatment with eculiz... Main characteristics of ravulizumab are described: composition, dosing, efficacy and safety profile. Further, an overview of seminal studies and clinical trials using ravulizumab to treat PNH and aHUS... Ravulizumab profile to treat PNH and aHUS is equivalent to eculizumab in efficacy and safety but allows extended dosing interval to every 4-8 weeks based on patient weight, and requires reduced infusi...

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method.

SB12 is being developed as a proposed biosimilar to eculizumab reference product (RP), a humanized monoclonal antibody (IgG2/4 kappa immunoglobulin) that binds to the human C5 complement protein. Bind... The objective of this study was to demonstrate structural, physicochemical, and biological similarity between eculizumab RP and SB12 using various state-of-the-art analytical methods.... Comprehensive analytical characterization was conducted with side-by-side comparison of SB12 with European Union (EU) and United States (US) eculizumab RPs using various analytical methods (more than ... Based on the analytical similarity assessment, the structural, physicochemical, and biological characterization results demonstrated that SB12 is highly similar to the EU and US eculizumab RP. In the ... In summary, the overall analytical characterization and similarity assessment results show that SB12 is highly similar to the EU and US eculizumab RP in terms of structural, physicochemical, biophysic...